Rationale, Design, and Methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE)

American Journal of Cardiology

Volumn 99, Issue 12 SUPPL., 2007, Pages

  Chew, Emily Y ^a   Ambrosius, Walter T ^b   Howard, Letitia T ^b   Greven, Craig M ^b   Johnson, Samantha ^c   Danis, Ronald P ^c   Davis, Matthew D ^c   Genuth, Saul ^d   Domanski, Michael ^e  

^a NATIONAL EYE INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE REGULATION; CATARACT EXTRACTION; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DYSLIPIDEMIA; EYE DISEASE; EYE EXAMINATION; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PHOTOGRAPHY; PRIORITY JOURNAL; STEREOSCOPIC VISION; SYSTOLIC BLOOD PRESSURE; VISUAL ACUITY; VITRECTOMY;

CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 34250694874     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.03.028     Document Type: Article

References (26)

1. Kempen J.H., O'Colmain B.J., Leske M.C., Haffner S.M., Klein R., Moss S.E., Taylor H.R., Hamman R.F., and Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122 (2004) 552-563
2. Klein R., Klein B.E.K., Moss S.E., and Cruickshanks K.J. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154 (1994) 2169-2178
3. Lloyd C.E., Klein R., Maser R.E., Kuller L.H., Becker D.J., and Orchard T.J. The progression of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. J Diabetes Complications 3 (1995) 140-148
4. Janka H.U., Warram J.H., Rand L.I., and Krolewski A.S. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 38 (1989) 460-464
5. Teuscher A., Schnell H., and Wilson P.W.F. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 11 (1988) 246-251
6. Marshall G., Garg S.K., Jackson W.E., Holmes D.L., and Chase H.P. Factors influencing the onset and progression of diabetic retinopathy in participants with insulin-dependent diabetes mellitus. Ophthalmology 100 (1993) 1133-1139
7. Krolewski A.S., Warram J.H., Rand L.I., Christlieb A.R., Busick E.J., and Kahn C.R. Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a 40-yr follow-up study. Diabetes Care 9 (1986) 443-552
8. Arfken C.L., Salicrup A.E., Meuer S.M., Del Priore L.V., Klein R., McGill J.B., Rucker C.S., White N.H., and Santiago J.V. Retinopathy in African Americans and whites with insulin-dependent diabetes mellitus. Arch Intern Med 154 (1994) 2597-2602
9. Krolewski A.S., Barzilay J., Warram J.H., Martin B.C., Pfeifer M., and Rand L.I. Risk of early-onset proliferative diabetic retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. Diabetes 41 (1992) 430-437
10. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol 113 (1995) 36-51
11. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002) 2563-2569
12. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) report VIII. Study design, progress and performance. Diabetologia 34 (1991) 877-890
13. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
14. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 317 (1998) 703-713
15. Klein B.E.K., Moss S.E., Klein R., and Surawicz T.S. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology 98 (1991) 1261-1265
16. Chew E.Y., Klein M.L., Ferris III F.L., Remaley N.A., Murphy R.P., Chantry K., Hoogwerf B.J., Miller D., and ETDRS Research Group. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Arch Ophthalmol 114 (1996) 1079-1084
17. ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99 suppl (2007) 21i-33i
18. Davis M.D., Fisher M.R., Gangnon R.E., Barton F., Aiello L.M., Chew E.Y., Ferris III F.L., and Knatterud G.L. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18. Invest Opthalmol Vis Sci 39 (1998) 233-252
19. Matthews D.R., Stratton I.M., Aldington S.J., Holman R.R., Kohner E.M., and UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 122 (2004) 1631-1640
20. Fong D.S., Segal P.P., Myers F., Ferris F.L., Hubbard L.D., Davis M.D., and Early Treatment Diabetic Retinopathy Study Research Group. Subretinal fibrosis in diabetic macular edema: ETDRS report 23. Arch Ophthalmol 115 (1997) 873-877
21. Kostraba J.N., Klein R., Dorman J.S., Becker D.J., Drash A.L., Maser R.E., and Orchard T.J. The Epidemiology of Diabetes Complications Study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 133 (1991) 381-391
22. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology 98 (1991) 786-806
23. Congdon N., O'Colmain B., Klaver C.C., Klein R., Munoz B., Friedman D.S., Kempen J., Taylor H.R., Mitchell P., and Eye Disease Prevalence Study Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
24. Colecciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 123 (2005) 1273-1312
25. Wolltorton E., and Kendall C. Rosiglitazone (Avandia) and macular edema. [health and drug alert]. CMAJ 174 (2006) 623
26. GlaxoSmithKline. Dear health care provider [letter]. [US FDA Web site.] Available at: http://www.fda.gov/medwatch/safety/2006/Avandia_DHCPletter.pdf. Accessed August 20, 2006.